Medicare Enrolled
Dr. Neeraj Mahajan, MD
Hematology & Oncology · Wadsworth, OH
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mahajan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mahajan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mahajan
Dr. Neeraj Mahajan is a hematology & oncology specialist in Wadsworth, OH, with 20 years of NPI registration. Based on federal Medicare data, Dr. Mahajan performed 832 Medicare services across 468 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mahajan received a total of $28,546 from 75 pharmaceutical and/or device companies across 457 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mahajan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 37% volume in OH
$28,546 industry payments
Medicare Practice Summary
Medicare Utilization ↗832
Medicare services
Top 37% in OH for hematology & oncology
468
Unique beneficiaries
$74
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~42 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
320 | $69 | $165 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
259 | $45 | $120 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
118 | $100 | $221 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
53 | $134 | $324 |
| New patient office visit, complex (60-74 min) | 52 | $129 | $319 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
30 | $58 | $115 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$28,546
Total received (2018-2024)
Avg $4,078/year across 7 years
Top 16% in OH for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
75
Companies
457
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$13,298 (46.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,148 (28.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,100 (24.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,747
2023
$3,032
2022
$2,311
2021
$11,297
2020
$5,583
2019
$2,555
2018
$1,021
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
TerSera Therapeutics LLC
$800
Novartis Pharmaceuticals Corporation
$210
ABBVIE INC.
$200
PFIZER INC.
$172
Merck Sharp & Dohme LLC
$141
Genentech USA, Inc.
$119
Janssen Biotech, Inc.
$97
Incyte Corporation
$74
Daiichi Sankyo Inc.
$68
AstraZeneca Pharmaceuticals LP
$67
E.R. Squibb & Sons, L.L.C.
$60
JAZZ PHARMACEUTICALS INC.
$58
Genmab U.S., Inc.
$52
Lilly USA, LLC
$47
Astellas Pharma US Inc
$45
Rigel Pharmaceuticals, Inc.
$43
EMD Serono, Inc.
$40
ADC Therapeutics America, Inc.
$38
Regeneron Healthcare Solutions, Inc.
$37
Boehringer Ingelheim Pharmaceuticals, Inc.
$35
Coherus Biosciences Inc.
$33
Celgene Corporation
$28
Tempus AI, Inc
$28
Alexion Pharmaceuticals, Inc.
$26
Eisai Inc.
$25
Pharmacosmos Therapeutics Inc.
$22
Novocure Inc.
$21
Exelixis Inc.
$21
GENZYME CORPORATION
$20
RECORDATI_RARE_DISEASES_INC.
$19
Aveo Pharmaceuticals, Inc.
$19
Gilead Sciences, Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$17
TAIHO ONCOLOGY, INC.
$17
Mirati Therapeutics, Inc.
$14
ARRAY BIOPHARMA INC
$13
Top 3 companies account for 44.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$3,969
PFIZER INC.
$3,134
GlaxoSmithKline, LLC.
$2,798
GENZYME CORPORATION
$1,756
Rigel Pharmaceuticals, Inc.
$1,315
Blueprint Medicines Corporation
$1,252
Daiichi Sankyo Inc.
$974
MACROGENICS, INC.
$900
BeiGene USA, Inc.
$877
TerSera Therapeutics LLC
$800
Novartis Pharmaceuticals Corporation
$776
AbbVie, Inc.
$758
Cepheid
$700
EMD Serono, Inc.
$574
BAXTER HEALTHCARE
$526
Genentech USA, Inc.
$421
Covis Pharma GmBH
$400
E.R. Squibb & Sons, L.L.C.
$397
Janssen Biotech, Inc.
$379
Seagen Inc.
$364
Melinta Therapeutics, LLC
$350
Athenex Pharmaceutical Division, LLC
$350
Dr.Reddy's Laboratories,Inc.
$350
Lilly USA, LLC
$339
Merck Sharp & Dohme LLC
$263
ABBVIE INC.
$247
Amgen Inc.
$223
Celgene Corporation
$205
Novocure GmbH
$200
Ipsen Biopharmaceuticals, Inc
$166
Incyte Corporation
$165
Astellas Pharma US Inc
$164
JAZZ PHARMACEUTICALS INC.
$151
Regeneron Healthcare Solutions, Inc.
$148
Boehringer Ingelheim Pharmaceuticals, Inc.
$145
Merck Sharp & Dohme Corporation
$130
Takeda Pharmaceuticals U.S.A., Inc.
$113
Pharmacyclics LLC, an AbbVie Company
$101
Bayer Healthcare Pharmaceuticals Inc.
$101
Cardinal Health 110 LLC
$100
ADC Therapeutics America, Inc.
$100
Pharmacyclics LLC, An AbbVie Company
$96
AVEO Pharmaceuticals, Inc.
$91
EISAI INC.
$87
MorphoSys, US Inc.
$85
Bayer HealthCare Pharmaceuticals Inc.
$72
EUSA Pharma (US) LLC
$67
Gilead Sciences, Inc.
$61
Alexion Pharmaceuticals, Inc.
$59
Blue Earth Diagnostics Limited
$55
Epizyme, Inc.,
$53
Genmab U.S., Inc.
$52
Eisai Inc.
$45
ARRAY BIOPHARMA INC
$44
Myovant Sciences Inc.
$43
Kite Pharma, Inc.
$41
Exelixis Inc.
$39
Coherus Biosciences Inc.
$33
TAIHO ONCOLOGY, INC.
$33
Adaptive Biotechnologies Corporation
$30
Tempus AI, Inc
$28
Telix Pharmaceuticals
$24
G1 Therapeutics, Inc.
$24
Puma Biotechnology, Inc.
$24
Pharmacosmos Therapeutics Inc.
$22
Novocure Inc.
$21
RECORDATI_RARE_DISEASES_INC.
$19
Aveo Pharmaceuticals, Inc.
$19
PUMA BIOTECHNOLOGY, INC.
$16
ImmunoGen, Inc.
$16
Mirati Therapeutics, Inc.
$14
Advanced Accelerator Applications
$13
Jazz Pharmaceuticals Inc.
$13
MEDIVATION FIELD SOLUTIONS LLC
$12
Clovis Oncology, Inc.
$10
Top 3 companies account for 34.7% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · AYVAKIT · Alecensa · Axumin · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · BioPharma Sol - Non Prod Related · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CYRAMZA · DAURISMO · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FASLODEX · FOTIVDA · Fabhalta · GAVRETO · GENEXPERT · GILOTRIF · Halaven · Herceptin · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Inrebic · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MARGENZA · MEKINIST · MONJUVI · NERLYNX · NO PRODUCT DISCUSSED · Nerlynx · Neulasta · Non-Franchise (NOF) - NonProduct · Nplate · Nubeqa · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Optune Lua (NovoTTF-200T) · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Phesgo · Polivy · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TUKYSA · Tavalisse · Tecentriq · Tepmetko · Tivdak · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · XTANDI · Xospata · Xtandi · ZEJULA · ZEPZELCA · ZIIHERA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (47%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
45
Per 100K population
24.6
County median income
$92,660
Nearest hospital
MEDINA HOSPITAL
8.4 mi
8.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mahajan is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 16% of OH peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mahajan experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Mahajan performed 320 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mahajan receive payments from pharmaceutical companies?
Yes. Dr. Mahajan received a total of $28,546 from 75 companies across 457 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mahajan's costs compare to other hematology & oncology specialists in Wadsworth?
Dr. Mahajan's average Medicare payment per service is $74. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mahajan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Wadsworth
Browse hematology & oncology specialists in Wadsworth ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in OH
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in OH
Which OH hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology